Full Press Release Details
BridgeBio Pharma Announces U.S. FDA Acceptance Of New Drug Application For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
BBIO
BridgeBio Pharma Announces U.S. FDA Acceptance Of New Drug Application For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Key Takeaway: BridgeBio Pharma Announces U.S. FDA Acceptance Of New Drug Application For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Price reaction · baseline $28.63 (2024-03-20 close) · hit after-hours · clean, no other BBIO news in the window
day 0 close
+1.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis